Came across this article this morning about Gossamer selling the rights to their new PAH drug, seralutinib, to Chiesi to compete with Merck's Winrevair.  The article states that analysts believe Winrevair sales could peak at between $1-8B.  Sounds like there may still be opportunity in this market for Apabetalone if management could actually get around to doing some business.

https://www.biopharmadive.com/news/gossamer-chiesi-pah-drug-merck-deal-license/715263/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202024-05-06%20BioPharma%20Dive%20%5Bissue:61782%5D&utm_term=BioPharma%20Dive